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Abstract
The human endometrium is an important site of innate immune defence, giving protection against
uterine infection. Such protection is critical to successful implantation and pregnancy. Infection is a
major cause of preterm birth and can also cause infertility and ectopic pregnancy. Natural anti-
microbial peptides are key mediators of the innate immune system. These peptides, between them,
have anti-bacterial, anti-fungal and anti-viral activity and are expressed at epithelial surfaces
throughout the female genital tract. Two families of natural anti-microbials, the defensins and the
whey acidic protein (WAP) motif proteins, appear to be prominent in endometrium. The human
endometrial epithelium expresses beta-defensins 1–4 and the WAP motif protein, secretory
leukocyte protease inhibitor. Each beta-defensin has a different expression profile in relation to the
stage of the menstrual cycle, providing potential protection throughout the cycle. Secretory
leukocyte protease inhibitor is expressed during the secretory phase of the cycle and has a range
of possible roles including anti-protease and anti-microbial activity as well as having effects on
epithelial cell growth. The leukocyte populations in the endometrium are also a source of anti-
microbial production. Neutrophils are a particularly rich source of alpha-defensins, lactoferrin,
lysozyme and the WAP motif protein, elafin. The presence of neutrophils during menstruation will
enhance anti-microbial protection at a time when the epithelial barrier is disrupted. Several other
anti-microbials including the natural killer cell product, granulysin, are likely to have a role in
endometrium. The sequential production of natural anti-microbial peptides by the endometrium
throughout the menstrual cycle and at other sites in the female genital tract will offer protection
from many pathogens, including those that are sexually transmitted.
Introduction
The key role of the human endometrium is to orchestrate
the events that lead to fertilization, implantation and
pregnancy. The prevention of uterine infection is crucial
to successful human reproduction and although the
endometrium must function as an efficient mucosal bar-
rier the passage of spermatozoa has to be accommodated.
The innate immune system in endometrium, as else-
where, must protect against infection while also signalling
the presence of a pathogen to the acquired immune sys-
tem in the event that infection does occur. Natural anti-
microbials are gene-encoded peptides that are key media-
tors of the innate immune system and the primary focus
of this review is to describe their expression in the human
endometrium
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The human endometrium undergoes characteristic cycli-
cal changes in response to the steroid hormones, oestra-
diol and progesterone. These have been described in
detail by Noyes et al [1]. In the first half of the menstrual
cycle (proliferative phase, days 4–13), when oestradiol
concentrations are increasing due to the development of a
follicle, the endometrium undergoes proliferation. Ovula-
tion occurs on day 14 of the cycle, the corpus luteum
forms and progesterone concentrations increase thereaf-
ter. Under the influence of progesterone endometrial
growth ceases and differentiation occurs in preparation
for implantation and pregnancy. The secretory function of
the endometrial glands increases with maximal secretion
in the mid secretory phase (days 19–23) around day 20.
In the late secretory phase (days 24–28) spiral arteriole
differentiation occurs and the stromal cells in immediate
proximity to these vessels differentiate (decidualize). The
nuclei of these cells become enlarged and the cytoplasmic
volume increases. These changes also occur in the stromal
cells below the surface epithelium and, if pregnancy
occurs, the entire endometrium decidualizes. In the
absence of implantation menstruation occurs resulting in
tissue breakdown and repair allowing regeneration of the
endometrium for the subsequent cycle. There are also
cyclical changes to the leukocyte populations present in
endometrium and these are described below.
Natural anti-microbials
The two major families of natural anti-microbials that will
be discussed in relation to endometrium are (i). defensins
and (ii). whey acidic protein (WAP) motif containing pro-
teins. Studies in other mucosal systems such as the respi-
ratory tract [2] strongly suggest that other anti-microbials
will also be active within the uterus.
Defensins
Defensins are a family of small cationic proteins that have
been shown to confer the host with anti-bacterial, anti-
fungal and anti-viral protection. Defensins have six
cysteine residues that form three disulphide bonds and
they are divided into two main groups on the basis of the
position of these bonds: α-defensins are found in neu-
trophils (human neutrophil peptides (HNP)1-4) and at
epithelial sites (human defensin (HD) 5 and 6) while the
β-defensins (human β defensins (HBD)) are found
mainly at epithelial surfaces e.g. gut, lung [3,4]. It has
recently been reported that there are 28 defensin-like
sequences in the human genome [5] but currently only
HBD1-6 have been characterized [6-11]. The β-defensins
further subdivide into those that are constitutively
expressed (e.g. HBD1) and those that are induced upon
challenge with inflammatory or pathogen-derived stimuli
[9,10,12-14]. In addition to their role as anti-microbials,
the β-defensins are chemoattractants allowing an interac-
tion between the innate and the acquired immune sys-
tems [8,9,15]. The expression, regulation and role of the
β-defensins at non-reproductive sites has been reviewed
elsewhere [16-18].
WAP motif containing proteins
Proteins containing the WAP motif have a 50 amino acid
domain, which forms a tight core containing four disul-
phide bonds [19]. This family includes secretory leukocyte
protease inhibitor (SLPI), elafin, eppin and HE4 [20].
SLPI and elafin are the most widely studied WAP proteins.
These two molecules share 40% homology, with eight
identical cysteines and five identical prolines, and both
are expressed at mucosal surfaces where they have anti-
protease and anti-microbial actions [21-26]. Both pro-
teins inhibit serine proteases with SLPI inhibiting several
proteases including neutrophil elastase and cathepsin G
[27] while elafin regulates only neutrophil elastase and
proteinase 3 [28-30]. These actions combined with their
anti-microbial activity allow SLPI and elafin to protect
epithelial surfaces during infection and inflammation.
The similarity between SLPI, elafin and other proteins
containing the WAP motif suggests that they may also
Representation of peak expression of the β-defensins, HBD1-4, and the WAP prot ins, SLPI and elafin, in endom trium throughout th  me stru l cycleFigure 1
Representation of peak expression of the β-defensins, 
HBD1-4, and the WAP proteins, SLPI and elafin, in 
endometrium throughout the menstrual cycle. HBD1, HBD3 
and SLPI are maximally expressed during the secretory 
phase. In contrast, expression of HBD4 is highest during the 
proliferative phase while HBD2 and elafin expression peaks 
during menstruation.Page 2 of 8
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surfaces [20].
Natural anti-microbial expression by the human 
endometrium
There are two main sites of natural anti-microbial expres-
sion in the endometrium: the epithelium and the leuko-
cyte populations that are an important component of the
cell types constituting the endometrium.
Natural anti-microbial expression by the endometrial 
epithelium
As at other mucosal surfaces the epithelial cell mediates
the initial response of the endometrium to infection [31].
In 1997 and 1998 the first reports of defensin expression
in the human endometrium were published. These
described the expression of the α-defensin, HD5, and the
β-defensin, HBD1, in the endometrial epithelium [32-
34]. Subsequently, messenger RNA (mRNA) for HBD1-4
has been detected in endometrium and it has been shown
that each defensin has a unique temporal expression pro-
file [35,36]. HBD1 and 3 are expressed at highest levels
during the secretory phase [35,36]. A similar pattern of
expression has been reported for HD5 [33]. In contrast,
HBD2 mRNA expression shows a dramatic peak during
menstruation while HBD4 is expressed mainly in the pro-
liferative phase [35,36]. These data are summarised in Fig-
ure 1. The reasons for these differential patterns of
expression have not been determined and may relate to
differences in anti-microbial activity of members of the
defensin family or to their other activities such as chemo-
taxis. Acquisition of sexually transmitted infections is
reported to be influenced by oestradiol and progesterone
[37] and changes to the expression of innate immune
molecules such as defensins may contribute to this. As in
other epithelial cells, expression of both HBD2 and 3 in
endometrial epithelial cells can be upregulated in
response to inflammatory stimuli suggesting that these
defensins will be induced in response to infection [36,38].
The WAP protein, SLPI, has also been detected in the
endometrial epithelium with peak expression in the mid-
late secretory phase (Figure 2a) [39]. This protein may
have important actions during the window of implanta-
tion. SLPI has several anti-inflammmatory actions includ-
ing inhibition of the proinflammatory transcription
factor, nuclear factor κB [40], and this combined with its
anti-protease activity may prevent an excessive inflamma-
tory response from occurring in the uterus at the time of
implantation and during early pregnancy. In addition,
SLPI has recently been suggested to have an effect on epi-
thelial growth. Proepithelin (PEPI) is an epithelial growth
factor that can be converted to a growth inhibitor, epithe-
lin (EPI), by elastase. SLPI can form a complex with PEPI
preventing its cleavage by elastase and hence, promote
epithelial growth [41]. In vitro studies using the Ishikawa
epithelial cell line (derived from an endometrial adeno-
carcinoma) have shown that SLPI can also increase expres-
sion of the cyclin D1 gene while inhibiting expression of
anti-proliferative genes such as insulin-like growth factor
binding protein-3 and lysyl oxidase [42]. The anti-micro-
bial actions of SLPI are likely to be particularly important
in the protection of the uterus from infection during
implantation and early pregnancy. Indeed, it has been
shown that the antibacterial activity of apical secretions
from polarized endometrial epithelial cells can be
reduced by incubation with an anti-SLPI antibody con-
firming that SLPI contributes to the antibacterial defences
at the epithelial surface at least in vitro [43]. SLPI concen-
trations and the ratio of SLPI to elastase have also been
found to increase in the peritoneal fluid of women suffer-
ing from endometriosis. Local peritoneal inflammation is
one of the factors thought to be responsible for the symp-
toms of this disease and it has been suggested that SLPI
concentrations are increased in response to this and that
the anti-inflammatory and anti-protease actions of SLPI
may limit the inflammatory process [44].
It is likely that the endometrial epithelium will also
express additional natural anti-microbials. For example,
the iron-binding protein lactoferrin is expressed by the
endometrial epithelium [45]. Lactoferrin has anti-micro-
bial actions [46] and has been shown to be oestrogen reg-
ulated with maximal expression in the proliferative phase
[47]. Lactoferrin has been shown to act in synergy with
SLPI [48] and it is likely that interactions between natural
anti-microbials in endometrium will also be important.
Immunohistochemical localization of the WAP proteins, SLPI and elafin, in human endometr umFigure 2
Immunohistochemical localization of the WAP proteins, SLPI 
and elafin, in human endometrium. (A). SLPI immunolocaliza-
tion in endometrium from the mid secretory phase. Immuno-
reactivity is present in the glandular epithelium and 
secretions. (B). Elafin immunolocalization in menstrual 
endometrium. Immunoreactivity is present in neutrophils 
infiltrating the endometrial stroma. Scale bars = 100 µm.Page 3 of 8
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leukocytes
Leukocyte populations are an important component of
the endometrium, constituting 8.2% of the stroma during
the proliferative phase with this figure increasing to
31.7% in first trimester decidua [49]. The presence of sev-
eral leukocyte populations in human endometrium is
cycle dependent. The populations of neutrophils, uterine
NK cells (uNK), macrophages and mast cells are relevant
to endometrial anti-microbial expression. uNK cells are
present in endometrium in the mid-late secretory phase of
the menstrual cycle and are the major leukocyte popula-
tion in first trimester decidua accounting for 70% of the
leukocytes present at this time [50]. They are believed to
have a role in implantation, decidualization and placenta-
tion [51]. uNK cells differ from the main population of
NK cells in peripheral blood as they are CD56bright [51].
The presence of these cells in endometrium is dependent
on progesterone although this may be an indirect action,
as uNK cells do not express the nuclear progesterone
receptor [52]. These cells express receptors for the gluco-
corticoid receptor and oestrogen receptor β suggesting
that they do respond to these steroid hormones [53]. Mac-
rophages are present throughout the cycle with a small
increase in number premenstrually [50,54]. There are also
increased numbers present in early pregnancy with a high
concentration found at the implantation site [55]. Imme-
diately prior to menstruation there is an influx of neu-
trophils into the endometrium [56]. Leukoctyes are
involved in the tissue breakdown and repair that occurs at
this time [57]. Infiltration of endometrium with both
neutrophils and macrophages around the time of men-
struation is coincident with falling progesterone concen-
trations. The effects of progesterone withdrawal on these
leukocyte populations is believed to be mediated by
increased expression of inflammatory mediators such as
interleukin-8 and monocyte chemoattractant protein-1 in
the endometrium premenstrually [58-60]. Mast cells are
also present throughout the menstrual cycle, although in
smaller numbers, and are activated at menstruation [61].
Neutrophils are a rich source of natural anti-microbial
molecules (Figure 3). The infiltration of the endometrium
by neutrophils during menstruation will enhance natural
anti-microbial protection at a time when the epithelial
barrier is disrupted. In addition, neutrophils will rapidly
infiltrate during infection, again increasing the innate
defences at an appropriate time. Peripheral blood neu-
trophils have been shown to express α-defensins, the
cathelicidin, human cationic anti-microbial peptide 18
(hCAP-18), lactoferrin and lysozyme [62-64]. It is likely
that endometrial neutrophils will also express these mol-
ecules although this has not yet been documented. More-
over, it is possible that the cytokine environment in the
uterus may, at certain stages of the menstrual cycle, mod-
ulate neutrophil granule release. The WAP protein, elafin,
has been detected in endometrial neutrophils (Figure 2b)
[65]. Elafin mRNA and protein expression rises dramati-
cally around the time of menstruation and immunohisto-
chemical studies have determined that the cellular source
of endometrial elafin is the neutrophil. The differing
expression profiles of the two WAP proteins, SLPI and
elafin (Figures 1 and 2), in endometrium suggest that they
have independent roles. The anti-protease actions of
elafin may aid tissue repair during menstruation while the
protein's anti-microbial activity will increase innate
immune defences at this time.
Granulysin is an anti-microbial molecule that is stored in
the granules of cytolytic T cells and peripheral blood NK
cells [66]. Granulysin mRNA has been found to be maxi-
mally expressed in endometrium from the late secretory
phase suggesting that the uNK cell is also a source of this
anti-microbial [35]. Expression of granulysin during the
late secretory phase may provide additional protection
around the time of implantation or in its absence,
menstruation.
It is also likely that endometrial macrophages and mast
cells will express natural anti-microbial peptides. There
are reports that HBD1 and 2 are expressed by blood
monocytes and alveolar macrophages [67] and that
hCAP-18 is expressed by human skin mast cells [68].
Natural anti-microbial expression in the human neutrophilFig e 3
Natural anti-microbial expression in the human neutrophil. 
Neutrophils contain two types of granules that contain natu-
ral anti-microbials. The azurophil granules contain α-
defensins while specific granules contain lactoferrin and the 
cathelicidin, hCAP-18. Lysozyme is present in both granule 
types.Page 4 of 8
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leukocytes has not yet been described.
Importance of natural anti-microbial expression 
to reproductive health
Mucosal surfaces of the endometrium do not act in isola-
tion to protect against infection. Anti-microbial peptides
are expressed at sites throughout the female reproductive
tract (Table 1) in order to protect the upper genital tract
and, in pregnancy, the developing fetus, from infection.
The consequences of such an infection include infertility,
ectopic pregnancy and preterm birth [69,70]. However,
little is known about the effects of contraceptive use on
natural anti-microbial expression.
The combined oral contraceptive pill (COCP) can alter
the susceptibility of users to pelvic infection. For example,
the prevalence of infection of the cervix with Chlamydia is
increased [71] while symptomatic Chlamydial infection
of the upper genital tract is decreased in COCP users com-
pared to non-users [72]. Oral contraceptive users are also
at higher risk of gonococcal infections [73]. These differ-
ences are likely to be due to several factors including
changes to the viscosity of cervical mucus, alterations to
cell mediated immunity and decreased menstrual blood
flow [37,74]. Changes to innate immune factors are also
likely to be important. Expression of the β-defensins,
HBD1-4, is suppressed in COCP users compared to peak
expression of these defensins in non-users suggesting that
innate immune defences are altered [35,36]. This may
have important consequences and it is clear that future
contraceptive design should ascertain the effects on anti-
microbial molecules. New contraceptives should not have
a deleterious effect on the innate immune system and ide-
ally, might enhance its actions.
Uterine infection is a major contributory factor in preterm
births [70]. There are studies that suggest that the expres-
sion of anti-microbial molecules is upregulated in
response to this situation. Concentrations of lactoferrin
increase in amniotic fluid in patients with intra-amniotic
infections, whether in preterm or term labour [75]. In
addition, levels of the α-defensins, HNP1-3, are increased
4–24 fold in patients in preterm labour suffering from
infection [76]. It is not yet clear whether or not any defects
in expression of anti-microbial molecules exist that may
increase susceptibility to uterine infections during preg-
nancy. The role of anti-microbials in the acquisition of
sexually transmitted infections has also not been fully
established although one study reports a decrease in SLPI
concentrations in vaginal fluid from women suffering
from lower genital tract infections [77]. In contrast, there
are reports to suggest that high concentrations of SLPI
may be beneficial in the limitation of spread of HIV. SLPI
has been shown to be the active component of saliva that
inhibits infection of monocytes with HIV [78] and there is
evidence to suggest that high concentrations of SLPI in
vaginal fluid reduce the likelihood that an infant will be
Table 1: Natural anti-microbial expression in the female reproductive tract.
Site of expression Anti-microbial Reference
Vagina HD5 [33]
HBD11 [34]
Elafin2 [81]
hCAP-18 [82]
Cervix HD5 [32,33]
HBD11 [34]
Elafin2 [81]
SLPI2 [83,84]
hCAP-18 [82]
Fallopian tube HD5 (variable) [33]
HBD11 [34]
SLPI2 [85]
First trimester decidua SLPI2 [39]
Amnion/Amniotic fluid SLPI2 [86,87]
Lactoferrin [88]
Term decidua SLPI2 [86]
Lactoferrin [88]
Chorion HD5 [32]
Placenta HNP1 or 3 [89]
HBD11 [90]
HBD31 [91]
1chemoattractant role 2anti-protease activityPage 5 of 8
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high concentrations of SLPI in infant saliva are reported to
offer protection against HIV transmission during breast-
feeding [80].
Conclusions
The human endometrium, in common with other
mucosal surfaces, produces a wide array of natural anti-
microbial peptides with the appearance of these peptides
appearing to be governed by the stage of the menstrual
cycle. These are expressed by both epithelial cells and
endometrial leukocytes and have the potential to provide
protection throughout the menstrual cycle and in preg-
nancy. The actions of these molecules may limit the
spread of sexually transmitted infections and prevent
against the uterine infections that cause preterm birth.
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